BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jennum PJ, Plazzi G, Silvani A, Surkin LA, Dauvilliers Y. Cardiovascular disorders in narcolepsy: Review of associations and determinants. Sleep Med Rev 2021;58:101440. [PMID: 33582582 DOI: 10.1016/j.smrv.2021.101440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Barateau L, Pizza F, Plazzi G, Dauvilliers Y. 50th anniversary of the ESRS in 2022-JSR special issue. J Sleep Res 2022;:e13631. [PMID: 35624073 DOI: 10.1111/jsr.13631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dauvilliers Y, Bogan RK, Šonka K, Partinen M, Foldvary-schaefer N, Thorpy MJ. Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy. NSS 2022;Volume 14:531-46. [DOI: 10.2147/nss.s279345] [Reference Citation Analysis]
3 Heo YA. Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use. CNS Drugs 2022. [PMID: 35357671 DOI: 10.1007/s40263-022-00912-6] [Reference Citation Analysis]
4 Barateau L, Lopez R, Chenini S, Rassu AL, Mouhli L, Dhalluin C, Jaussent I, Dauvilliers Y. Linking clinical complaints and objective measures of disrupted nighttime sleep in narcolepsy type 1. Sleep 2022;45:zsac054. [PMID: 35275598 DOI: 10.1093/sleep/zsac054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Grandner MA, Fernandez FX. The translational neuroscience of sleep: A contextual framework. Science 2021;374:568-73. [PMID: 34709899 DOI: 10.1126/science.abj8188] [Reference Citation Analysis]
6 Mogavero MP, Silvani A, DelRosso LM, Salemi M, Ferri R. Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity. Cancers (Basel) 2021;13:2612. [PMID: 34073579 DOI: 10.3390/cancers13112612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Naguy A, Singh Solanki AP, Alamiri B. Newly FDA-approved psychotropic agents-a recap. Asian J Psychiatr 2021;64:102786. [PMID: 34298485 DOI: 10.1016/j.ajp.2021.102786] [Reference Citation Analysis]
8 Bock J, Covassin N, Somers V. Excessive daytime sleepiness: an emerging marker of cardiovascular risk. Heart. [DOI: 10.1136/heartjnl-2021-319596] [Reference Citation Analysis]
9 Junnarkar G, Allphin C, Profant J, Steininger TL, Chen C, Zomorodi K, Skowronski R, Black J. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. Expert Opin Drug Discov 2021;:1-11. [PMID: 34818123 DOI: 10.1080/17460441.2022.1999226] [Reference Citation Analysis]
10 Pavkovic IM, Kothare SV. Pharmacologic Approaches to Insomnia and Other Sleep Disorders in Children. Curr Treat Options Neurol. [DOI: 10.1007/s11940-022-00712-9] [Reference Citation Analysis]